Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, multicenter, randomized, double-blind, comparative study to evaluate the safety and efficacy of ceftaroline [ceftaroline fosamil] versus ceftriaxone in the treatment of adult subjects with community-acquired pneumonia.

Trial Profile

A phase 3, multicenter, randomized, double-blind, comparative study to evaluate the safety and efficacy of ceftaroline [ceftaroline fosamil] versus ceftriaxone in the treatment of adult subjects with community-acquired pneumonia.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs Ceftaroline fosamil (Primary) ; Ceftriaxone
  • Indications Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms FOCUS-2; FOCUS-II
  • Sponsors Cerexa; Forest Laboratories
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 24 Apr 2018 Results assessing comparison of safety profile of two regimens of ceftaroline fosamil by using data from six phase III studies (COVERS, CANVAS 1, CANVAS 2, FOCUS 1, FOCUS 2, and asian CAP) presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
    • 05 Jun 2017 Results of subgroup analysis from two phase III studies (FOCUS-1 and FOCUS-2) presented at the ASM Microbe 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top